New fatty liver drug enters first human tests
NCT ID NCT07214870
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This early-stage study tests whether a new medicine called NNC4005-0001 is safe and tolerable for people with excess weight and fatty liver. About 60 adults will receive either the drug or a placebo, and the study lasts 7–8 months. The goal is to check for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Company, Inc
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.